bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas
Authors: Eruslanov Evgeniy , Stoffs Taryn , Kim Wan-Ju , Daurkin Irina , Gilbert Scott M. , Su Li-Ming , Vieweg Johannes , Daaka Yehia , Kusmartsev Sergei
Published: April 2023

PDF file - 70K, CCR8+ myeloid cells induce FoxP3 expression in T cells
Data Supplement from Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts
Authors: Cottu Paul , Bièche Ivan , Assayag Franck , El Botty Rania , Chateau-Joubert Sophie , Thuleau Aurélie , Bagarre Thomas , Albaud Benoit , Rapinat Audrey , Gentien David , de la Grange Pierre , Sibut Vonick , Vacher Sophie , Hatem Rana , Servely Jean-Luc , Fontaine Jean-Jacques , Decaudin Didier , Pierga Jean-Yves , Roman-Roman Sergio , Marangoni Elisabetta
Published: April 2023

Supplementary Table S2. P-S6 IHC scores corresponding to tumors from the 3 TMA.
Supplementary Table 1 from The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials
Authors: Iasonos Alexia , Gounder Mrinal , Spriggs David R. , Gerecitano John F. , Hyman David M. , Zohar Sarah , O'Quigley John
Published: April 2023

PDF file, 50K, Supp. Table 1. Dose-escalation algorithm for 3+3 method.
Supplementary Table S1 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Alves Carla L. , Elias Daniel , Lyng Maria , Bak Martin , Kirkegaard Tove , Lykkesfeldt Anne E. , Ditzel Henrik J.
Published: April 2023

Alteration in gene expression of the cyclin D/CDK4-6/p16INK4a/Rb pathway in endocrine-resistant cell line models as determined by gene array.
Supplementary Figure S5 from Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy
Authors: Khan Sofia , Fagerholm Rainer , Rafiq Sajjad , Tapper William , Aittomäki Kristiina , Liu Jianjun , Blomqvist Carl , Eccles Diana , Nevanlinna Heli
Published: April 2023

Supplementary Figure S5. Regional plot using P-values derived from univariate Cox's regression model from HEBCS and POSH GWS meta-analysis and includes both imputed and the genotyped SNPs 250 kb either side of the rs8113308.
Supplementary Figure S3 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Alves Carla L. , Elias Daniel , Lyng Maria , Bak Martin , Kirkegaard Tove , Lykkesfeldt Anne E. , Ditzel Henrik J.
Published: April 2023

Parallel micrographs of FFPE fulvestrant-resistant and parental breast cancer cell lines and clinical metastatic samples exhibiting comparable CDK6 levels.
Supplementary Figure S2 from Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy
Authors: Khan Sofia , Fagerholm Rainer , Rafiq Sajjad , Tapper William , Aittomäki Kristiina , Liu Jianjun , Blomqvist Carl , Eccles Diana , Nevanlinna Heli
Published: April 2023

Supplementary Figure S2. Kaplan-Meier plots of cumulative breast cancer specific 10-year survival of rs8113308 genotypes in HEBCS GWS
Supplementary Figure S1 from Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy
Authors: Khan Sofia , Fagerholm Rainer , Rafiq Sajjad , Tapper William , Aittomäki Kristiina , Liu Jianjun , Blomqvist Carl , Eccles Diana , Nevanlinna Heli
Published: April 2023

Supplementary Figure S1. REMARK diagram describing work flow and sample selection in this study.
Supplementary Table 1-4, Supplementary Figure 1-2 from Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics
Authors: Haake Scott M. , Li Jiannong , Bai Yun , Kinose Fumi , Fang Bin , Welsh Eric A. , Zent Roy , Dhillon Jasreman , Pow-Sang Julio M. , Chen Y. Ann , Koomen John M. , Rathmell W. Kimryn , Fishman Mayer , Haura Eric B.
Published: April 2023

Supplementary Table 1: Clinical characteristics of patients whose tumors were utilized for phosphotyrosine peptide survey. Supplementary Table 2: Phosphorylated Proteins in RCC Cell Line and Tumor Samples. Supplementary Table 3: Phosphopeptides identified using the Andromeda search engine of 10 renal cell carcinoma cell lines. Supplementary Table 4: Supplementary Table 4. Label-free quantification of phosphopeptides identified using the Andromeda search engine of 15 clear cell and 15 papillary renal cell carcinoma tumors. Supplementary Figure 1: Tyrosine kinase inhibitors (0.5 μM) provide functional correlation. Supplementary Figure 2: Tyrosine kinase inhibitors (2.5 μM) provide functional correlation. Please note that this data, due to its large size, is represented best in Microsoft Excel.
Supplementary figure 5 from TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Authors: Peeters Sarah G.J.A. , Zegers Catharina M.L. , Biemans Rianne , Lieuwes Natasja G. , van Stiphout Ruud G.P.M. , Yaromina Ala , Sun Jessica D. , Hart Charles P. , Windhorst Albert D. , van Elmpt Wouter , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary figure 5. Quantification of H460 histological staining for A) necrotic fraction (NF), B) relative vessel area (RVA), C) perfusion fraction (PF) and D) relative perfusion area (RPA). Data represent mean {plus minus} SEM.
Supplementary Figure 5 from Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics
Authors: Haake Scott M. , Li Jiannong , Bai Yun , Kinose Fumi , Fang Bin , Welsh Eric A. , Zent Roy , Dhillon Jasreman , Pow-Sang Julio M. , Chen Y. Ann , Koomen John M. , Rathmell W. Kimryn , Fishman Mayer , Haura Eric B.
Published: April 2023

Immunohistochemistry demonstrates robust DDR1 phosphorylation in papillary RCC tumors.
Supplementary figure 2 from TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Authors: Peeters Sarah G.J.A. , Zegers Catharina M.L. , Biemans Rianne , Lieuwes Natasja G. , van Stiphout Ruud G.P.M. , Yaromina Ala , Sun Jessica D. , Hart Charles P. , Windhorst Albert D. , van Elmpt Wouter , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary figure 2. Optimal TH-302 dose assessment for rhabdomyosarcoma bearing rats. Animals were treated on 4 consecutive days with either the control (NaCl), 25, 50 or 75mg/kg TH-302. Tumor volume (A) and body weight (B) was monitored over time. Data represent mean {plus minus} SEM, for all groups n=9.
Supplementary Methods from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Authors: Rao Mahadev , Atay Scott M. , Shukla Vivek , Hong Young , Upham Trevor , Ripley R. Taylor , Hong Julie A. , Zhang Mary , Reardon Emily , Fetsch Patricia , Miettinen Markku , Li Xinmin , Peer Cody J. , Sissung Tristan , Figg William D. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

Supplementary Material and Methods
Supplementary Figure S4 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Authors: Rao Mahadev , Atay Scott M. , Shukla Vivek , Hong Young , Upham Trevor , Ripley R. Taylor , Hong Julie A. , Zhang Mary , Reardon Emily , Fetsch Patricia , Miettinen Markku , Li Xinmin , Peer Cody J. , Sissung Tristan , Figg William D. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

Effect of mithramycin on target gene promoters.
Supplemental Figure 2 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
Authors: Martínez-Vélez Naiara , Xipell Enric , Vera Beatriz , Acanda de la Rocha Arlet , Zalacain Marta , Marrodán Lucía , Gonzalez-Huarriz Marisol , Toledo Gemma , Cascallo Manel , Alemany Ramón , Patiño Ana , Alonso Marta M.
Published: April 2023

Supplemental Figure 2
Supplemental Figure 1 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
Authors: Martínez-Vélez Naiara , Xipell Enric , Vera Beatriz , Acanda de la Rocha Arlet , Zalacain Marta , Marrodán Lucía , Gonzalez-Huarriz Marisol , Toledo Gemma , Cascallo Manel , Alemany Ramón , Patiño Ana , Alonso Marta M.
Published: April 2023

Supplemental Figure 1
Supplementary Table S1 from Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Authors: Morikawa Aki , Henry N. Lynn
Published: April 2023

Targeted therapy currently being evaluated in ER+, HER2- metastatic breast cancer patients
Supplemental Figure from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Authors: Lee Eudocia Q. , Kaley Thomas J. , Duda Dan G. , Schiff David , Lassman Andrew B. , Wong Eric T. , Mikkelsen Tom , Purow Benjamin W. , Muzikansky Alona , Ancukiewicz Marek , Huse Jason T. , Ramkissoon Shakti , Drappatz Jan , Norden Andrew D. , Beroukhim Rameen , Weiss Stephanie E. , Alexander Brian M. , McCluskey Christine S. , Gerard Mary , Smith Katrina H. , Jain Rakesh K. , Batchelor Tracy T. , Ligon Keith L. , Wen Patrick Y.
Published: April 2023

Supplemental Figure: Mean plasma concentrations of vandetanib.
Supplementary Figure 4 from Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma
Authors: Nguyen Phu Hung , Giraud Julie , Chambonnier Lucie , Dubus Pierre , Wittkop Linda , Belleannée Geneviève , Collet Denis , Soubeyran Isabelle , Evrard Serge , Rousseau Benoit , Senant-Dugot Nathalie , Mégraud Francis , Mazurier Frédéric , Varon Christine
Published: April 2023

Effect of verapamil treatment in combination with chemotherapies on tumorsphere formation by GC10.
Supplementary Figure 3 from Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
Authors: Al-Ejeh Fares , Pajic Marina , Shi Wei , Kalimutho Murugan , Miranda Mariska , Nagrial Adnan M. , Chou Angela , Biankin Andrew V. , Grimmond Sean M. , Brown Michael P. , Khanna Kum Kum
Published: April 2023

Supplementary Figure 3: EGFR expression in the PANC-1 and BxPC-3. Cell cultures were used for standard immunoblot and flow cytometry analysis for EGFR expression. The anti-EGFR mAb clone 225 was used for staining and anti-mouse IgG antibody conjugated with HRP was used for immunoblot or conjugated with Alexa488 for flow cytometry. Anti-tubulin was used to confirm equal loading for immunoblot. Both PDAC cell lines express EGFR.
Table S3 from Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Authors: Morita Rena , Hirohashi Yoshihiko , Torigoe Toshihiko , Ito-Inoda Satoko , Takahashi Akari , Mariya Tasuku , Asanuma Hiroko , Tamura Yasuaki , Tsukahara Tomohide , Kanaseki Takayuki , Kubo Terufumi , Kutomi Goro , Mizuguchi Toru , Terui Takeshi , Ishitani Kunihiko , Hashino Satoshi , Kondo Toru , Minagawa Nozomi , Takahashi Norihiko , Taketomi Akinobu , Todo Satoru , Asaka Masahiro , Sato Noriyuki
Published: April 2023

Summary of the OR7C1 peptides carrying HLA-A24 binding motief.
Table S1 from Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Authors: Morita Rena , Hirohashi Yoshihiko , Torigoe Toshihiko , Ito-Inoda Satoko , Takahashi Akari , Mariya Tasuku , Asanuma Hiroko , Tamura Yasuaki , Tsukahara Tomohide , Kanaseki Takayuki , Kubo Terufumi , Kutomi Goro , Mizuguchi Toru , Terui Takeshi , Ishitani Kunihiko , Hashino Satoshi , Kondo Toru , Minagawa Nozomi , Takahashi Norihiko , Taketomi Akinobu , Todo Satoru , Asaka Masahiro , Sato Noriyuki
Published: April 2023

Summary of genes overexpressed in SP cells
Figure S3 from Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Authors: Morita Rena , Hirohashi Yoshihiko , Torigoe Toshihiko , Ito-Inoda Satoko , Takahashi Akari , Mariya Tasuku , Asanuma Hiroko , Tamura Yasuaki , Tsukahara Tomohide , Kanaseki Takayuki , Kubo Terufumi , Kutomi Goro , Mizuguchi Toru , Terui Takeshi , Ishitani Kunihiko , Hashino Satoshi , Kondo Toru , Minagawa Nozomi , Takahashi Norihiko , Taketomi Akinobu , Todo Satoru , Asaka Masahiro , Sato Noriyuki
Published: April 2023

OR7C1 gene knockdown experiments
Supplementary material and Supplementary table 1 from A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Authors: Diaz-Lagares Angel , Mendez-Gonzalez Jesus , Hervas David , Saigi Maria , Pajares Maria J. , Garcia Diana , Crujerias Ana B. , Pio Ruben , Montuenga Luis M. , Zulueta Javier , Nadal Ernest , Rosell Antoni , Esteller Manel , Sandoval Juan
Published: April 2023

Study design participants, supplementary figure legends and List of cancer-related differentially methylated CpGs
Figure S2 from Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Authors: Morita Rena , Hirohashi Yoshihiko , Torigoe Toshihiko , Ito-Inoda Satoko , Takahashi Akari , Mariya Tasuku , Asanuma Hiroko , Tamura Yasuaki , Tsukahara Tomohide , Kanaseki Takayuki , Kubo Terufumi , Kutomi Goro , Mizuguchi Toru , Terui Takeshi , Ishitani Kunihiko , Hashino Satoshi , Kondo Toru , Minagawa Nozomi , Takahashi Norihiko , Taketomi Akinobu , Todo Satoru , Asaka Masahiro , Sato Noriyuki
Published: April 2023

OR7C1 gene overexpression experiments
Figure S1 from Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Authors: Morita Rena , Hirohashi Yoshihiko , Torigoe Toshihiko , Ito-Inoda Satoko , Takahashi Akari , Mariya Tasuku , Asanuma Hiroko , Tamura Yasuaki , Tsukahara Tomohide , Kanaseki Takayuki , Kubo Terufumi , Kutomi Goro , Mizuguchi Toru , Terui Takeshi , Ishitani Kunihiko , Hashino Satoshi , Kondo Toru , Minagawa Nozomi , Takahashi Norihiko , Taketomi Akinobu , Todo Satoru , Asaka Masahiro , Sato Noriyuki
Published: April 2023

Isolation of colon CICs as SP cells and the expression of OR7C1
Supplementary Figure 4 from A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Authors: Diaz-Lagares Angel , Mendez-Gonzalez Jesus , Hervas David , Saigi Maria , Pajares Maria J. , Garcia Diana , Crujerias Ana B. , Pio Ruben , Montuenga Luis M. , Zulueta Javier , Nadal Ernest , Rosell Antoni , Esteller Manel , Sandoval Juan
Published: April 2023

Epigenetic signature in lung cancer and non-tumoral paraffins classified based on histological subtypes.
Supplementary Table 4 from PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Authors: Field Matthew G. , Decatur Christina L. , Kurtenbach Stefan , Gezgin Gülçin , van der Velden Pieter A. , Jager Martine J. , Kozak Kaleigh N. , Harbour J. William
Published: April 2023

Significance Analysis of Microarrays (SAM) for differentially expressed genes between Class1met+ tumors and Class1met- tumors.
Supplemental methods from The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
Authors: Lolkema Martijn P. , Bohets Hilde H. , Arkenau Hendrik-Tobias , Lampo Ann , Barale Erio , de Jonge Maja J.A. , van Doorn Leni , Hellemans Peter , de Bono Johann S. , Eskens Ferry A.L.M.
Published: April 2023

Supplemental methods. additional description of methods
Supplmentary Documents including Methods, Tables, and Legends for Supplementary Figures, and Supplementary Figure S1-S5 from Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Authors: Xu-Monette Zijun Y. , Deng Qipan , Manyam Ganiraju C. , Tzankov Alexander , Li Ling , Xia Yi , Wang Xiao-xiao , Zou Dehui , Visco Carlo , Dybkær Karen , Li Jun , Zhang Li , Liang Han , Montes-Moreno Santiago , Chiu April , Orazi Attilio , Zu Youli , Bhagat Govind , Richards Kristy L. , Hsi Eric D. , Choi William W.L. , van Krieken J. Han , Huh Jooryung , Ponzoni Maurilio , Ferreri Andrés J.M. , Parsons Ben M. , Møller Michael B. , Wang Sa A. , Miranda Roberto N. , Piris Miguel A. , Winter Jane N. , Medeiros L. Jeffrey , Li Yong , Young Ken H.
Published: April 2023

The supplementary documents include: (1) Supplementary methods for detection of MYC mutations and rearrangements, assessment of Myc expression, and functional studies. (2) Supplementary Tables S1-S8. Supplementary Table S1. Numbers of MYC mutation present in the coding sequence and the untranslated regions. Supplementary Table S2. Clinical and molecular characteristics of the DLBCL cohort with wild-type or mutated Myc or N11S single nucleotide polymorphism. Supplementary Table S3. List of Myc mutations and corresponding patient survival. Supplementary Table S4. Multivariate survival analysis. Supplementary Table S5. Molecular characteristics of patients with wild-type or mutated MYC untranslated regions. Supplementary Table S6. List of MYC 3Ã,'UTR mutations and corresponding patient survival. Supplementary Table S7. Gene profiling comparisons between wild-type and mutated MYC. Supplementary Table S8. Brief summary of major findings by this study. (3) Legends for Supplementary Figures S1-S5. Supplementary Figure S1. Survival analysis for MYC mutations in DLBCL respective to GCB/ABC subtypes, homo/heterozygosity, and MYC translocations. Supplementary Figure S2. Comparison of Myc levels and gene expression profiles between DLBCL groups. Supplementary Figure S3. Differential expression of genes between the WT-Myc and MUT-Myc groups. Supplementary Figure S4. Comparison of gene expression between the WT-Myc and MUT-Myc groups. Supplementary Figure S5. Differential expression of proteins between the WT-Myc and MUT-Myc groups.
Supplementary Figure 1 from PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Authors: Field Matthew G. , Decatur Christina L. , Kurtenbach Stefan , Gezgin Gülçin , van der Velden Pieter A. , Jager Martine J. , Kozak Kaleigh N. , Harbour J. William
Published: April 2023

Statistical, molecular, and survival analyses.
Supplementary Figures 1-3 from Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer
Authors: Straetemans Trudy , Gründer Cordula , Heijhuurs Sabine , Hol Samantha , Slaper-Cortenbach Ineke , Bönig Halvard , Sebestyen Zsolt , Kuball Jürgen
Published: April 2023

Supplementary Figures 1-3. Fig S1. Representative result of retroviral transduction with γδTCR transgene cassettes shows increased γδTCR expression with γ-T2A-δ cassette Fig S2. Fast and increased re-expression of retrovirally introduced TCR following T cell stimulation. Fig S3. Prevention of multiple myeloma growth by purified γδTCR transduced T cells in vivo.
Supplemental Figure 5 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Authors: Jackson Christopher M. , Kochel Christina M. , Nirschl Christopher J. , Durham Nicholas M. , Ruzevick Jacob , Alme Angela , Francica Brian J. , Elias Jimmy , Daniels Andrew , Dubensky Thomas W. , Lauer Peter , Brockstedt Dirk G. , Baxi Emily G. , Calabresi Peter A. , Taube Janis M. , Pardo Carlos A. , Brem Henry , Pardoll Drew M. , Lim Michael , Drake Charles G.
Published: April 2023

Tumor Morphology and Volume Upon Death. A) Morphology of tumors calculated using ex vivo MRI as described. B) Calculated brain tumor volumes at the time of death as determined by ex vivo MRI (N = 3 mice/group).
Supplemental Figure 4 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Authors: Jackson Christopher M. , Kochel Christina M. , Nirschl Christopher J. , Durham Nicholas M. , Ruzevick Jacob , Alme Angela , Francica Brian J. , Elias Jimmy , Daniels Andrew , Dubensky Thomas W. , Lauer Peter , Brockstedt Dirk G. , Baxi Emily G. , Calabresi Peter A. , Taube Janis M. , Pardo Carlos A. , Brem Henry , Pardoll Drew M. , Lim Michael , Drake Charles G.
Published: April 2023

: PD-1 blockade does not add to RT + Vaccination. Adding PD-1 blockade to RT + rLM-OVA does not significantly improve survival in mice with B16-OVA brain tumors. (N = 10 animals / group)
Supplemental Table S4 from Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Authors: Hirbe Angela C. , Dahiya Sonika , Miller Christopher A. , Li Tiandao , Fulton Robert S. , Zhang Xiaochun , McDonald Sandra , DeSchryver Katherine , Duncavage Eric J. , Walrath Jessica , Reilly Karlyne M. , Abel Haley J. , Pekmezci Melike , Perry Arie , Ley Timothy J. , Gutmann David H.
Published: April 2023

Supplemental Table S4. Mutations Identified in the Discovery Patient
Supplemental Table S3 from Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Authors: Hirbe Angela C. , Dahiya Sonika , Miller Christopher A. , Li Tiandao , Fulton Robert S. , Zhang Xiaochun , McDonald Sandra , DeSchryver Katherine , Duncavage Eric J. , Walrath Jessica , Reilly Karlyne M. , Abel Haley J. , Pekmezci Melike , Perry Arie , Ley Timothy J. , Gutmann David H.
Published: April 2023

Supplemental Table S3. Copy Number Alterations Recurrent Across Studies
Supplemental Table S2 from Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Authors: Hirbe Angela C. , Dahiya Sonika , Miller Christopher A. , Li Tiandao , Fulton Robert S. , Zhang Xiaochun , McDonald Sandra , DeSchryver Katherine , Duncavage Eric J. , Walrath Jessica , Reilly Karlyne M. , Abel Haley J. , Pekmezci Melike , Perry Arie , Ley Timothy J. , Gutmann David H.
Published: April 2023

Supplemental Table S2. Copy Number Calls
Supplemental Figure S2 from Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Authors: Hirbe Angela C. , Dahiya Sonika , Miller Christopher A. , Li Tiandao , Fulton Robert S. , Zhang Xiaochun , McDonald Sandra , DeSchryver Katherine , Duncavage Eric J. , Walrath Jessica , Reilly Karlyne M. , Abel Haley J. , Pekmezci Melike , Perry Arie , Ley Timothy J. , Gutmann David H.
Published: April 2023

Supplemental Figure S2. Copy number plots depicting few copy number changes in Plexiform 1 (A), Plexiform 2 (B), Plexiform 3 (C), and Low-Grade MPNST within Plexiform (D).
Supplementary Figure 2 from Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy
Authors: Catalano Stefania , Campana Antonella , Giordano Cinzia , Győrffy Balázs , Tarallo Roberta , Rinaldi Antonio , Bruno Giuseppina , Ferraro Aurora , Romeo Francesco , Lanzino Marilena , Naro Fabio , Bonofiglio Daniela , Andò Sebastiano , Barone Ines
Published: April 2023

Effects of PDE5 overexpression on c-Myc and NF-κB Activation.
Supplementary Figure 1 from Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy
Authors: Catalano Stefania , Campana Antonella , Giordano Cinzia , Győrffy Balázs , Tarallo Roberta , Rinaldi Antonio , Bruno Giuseppina , Ferraro Aurora , Romeo Francesco , Lanzino Marilena , Naro Fabio , Bonofiglio Daniela , Andò Sebastiano , Barone Ines
Published: April 2023

Molecule activity predictor analysis of Ingenuity Pathway Analysis performed on Cdc42 signaling and Rac signaling in PDE5-overexpressing MCF-7 cells compared to vector-transfected cells.
Supplemental Tables 1-7 from Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Authors: Mansfield Aaron S. , Murphy Stephen J. , Peikert Tobias , Yi Eunhee S. , Vasmatzis George , Wigle Dennis A. , Aubry Marie Christine
Published: April 2023

Supplemental Table 1: The specimen characteristics with staining results and lineage relationships; Supplemental Table 2: Contingency table of PD-L1 expression agreement by tumor cells amongst all paired lesions; Supplemental Table 3: Contingency table of PD-L1 expression agreement between tumor cells and immune cells; Supplemental Table 4: Contingency table of PD-L1 expression agreement by tumor cells amongst independent primary lesions; Supplemental Table 5: Contingency table of PD-L1 expression agreement by immune cells amongst independent primary lesions; Supplemental Table 6: Contingency table of PD-L1 expression agreement by tumor cells amongst related lesions; Supplemental Table 7: Contingency table of PD-L1 expression agreement by immune cells amongst related lesions
Supplementary figures 1-4 from Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Authors: Cioffi Michele , Trabulo Sara , Hidalgo Manuel , Costello Eithne , Greenhalf William , Erkan Mert , Kleeff Joerg , Sainz Bruno , Heeschen Christopher
Published: April 2023

Supplementary figures 1-4. Supplementary Figure 1 - CD47 expression in pancreatic cancer (stem) cells; Supplementary Figure 1 - CD47 expression in pancreatic cancer (stem) cells; Supplementary Figure 2 - Anti-CD47 effects in a ratio 1:1 with pancreatic cancer stem cells; Supplementary Figure 3 - Apoptosis induction after CD47 treatment; Supplementary Figure 4 - Histological analysis following in vivo treatment
Supplementary Table 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Authors: Leary Alexandra , Evans Abigail , Johnston Stephen R.D. , A'Hern Roger , Bliss Judith M. , Sahoo Rashmita , Detre Simone , Haynes Benjamin P. , Hills Margaret , Harper-Wynne Catherine , Bundred Nigel , Coombes Gill , Smith Ian , Dowsett Mitch
Published: April 2023

Supplementary Table 3. Correlation between baseline protein and mRNA expression biomarker values with Ki67 response (defined as >50% fall in Ki67).
Supplementary Table 2 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Authors: Leary Alexandra , Evans Abigail , Johnston Stephen R.D. , A'Hern Roger , Bliss Judith M. , Sahoo Rashmita , Detre Simone , Haynes Benjamin P. , Hills Margaret , Harper-Wynne Catherine , Bundred Nigel , Coombes Gill , Smith Ian , Dowsett Mitch
Published: April 2023

Supplementary Table 2. Biomarker changes in placebo treated arm.
Supplemental Methods and Figure Legends from The Renin–Angiotensin System Mediates EGF Receptor–Vitamin D Receptor Cross-Talk in Colitis-Associated Colon Cancer
Authors: Dougherty Urszula , Mustafi Reba , Sadiq Farhana , Almoghrabi Anas , Mustafi Devkumar , Kreisheh Maggi , Sundaramurthy Sumana , Liu Weicheng , Konda Vani J. , Pekow Joel , Khare Sharad , Hart John , Joseph Loren , Wyrwicz Alice , Karczmar Gregory S. , Li Yan Chun , Bissonnette Marc
Published: April 2023

Supplemental Methods and Figure Legends
Supplemental Figure S2 from The Renin–Angiotensin System Mediates EGF Receptor–Vitamin D Receptor Cross-Talk in Colitis-Associated Colon Cancer
Authors: Dougherty Urszula , Mustafi Reba , Sadiq Farhana , Almoghrabi Anas , Mustafi Devkumar , Kreisheh Maggi , Sundaramurthy Sumana , Liu Weicheng , Konda Vani J. , Pekow Joel , Khare Sharad , Hart John , Joseph Loren , Wyrwicz Alice , Karczmar Gregory S. , Li Yan Chun , Bissonnette Marc
Published: April 2023

Supplemental Figure S2. EGF induces Snail in HT29 colon cancer cells. Cells were plated on collagen-coated 6 well plates in 10% serum. Twenty-four hrs later cells were deprived of serum and treated with vehicle (phosphate-buffered saline), 10 ng/ml EGF or 40 ng/ml TGFÎ². After 72 hrs cells were lysed and extracts probed for indicated proteins. Shown are blots representative of three independent platings.
Supplementary Figure 3 from Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
Authors: Luchman H. Artee , Stechishin Owen D.M. , Nguyen Stephanie A. , Lun Xueqing Q. , Cairncross J. Gregory , Weiss Samuel
Published: April 2023

Rapamycin partially inhibits growth of most BTICs irrespective of EGFR or PTEN mutational status.
supplemental figure legend from Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Authors: Zhang Libo , Marrano Paula , Wu Bing , Kumar Sushil , Thorner Paul , Baruchel Sylvain
Published: April 2023

supplemental figure legend
Supplementary Figure 3 from Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Authors: Zhang Libo , Marrano Paula , Wu Bing , Kumar Sushil , Thorner Paul , Baruchel Sylvain
Published: April 2023

Increased ROS in neuroblastoma and rhabdomyosarcoma cells under hypoxia. The generation of intracellular oxidative activities was evaluated by measuring intracellular peroxide-dependent oxidation of 2â€²,7â€²-dichlorodihydrofluorescein diacetate (DCFDA, Sigma D6883) to form the fluorescent compound, 2â€²,7â€²-dichlorofluorescein (DCF) (50). Tumor cells were cultured in 96-well culture plates. After culturing overnight under normoxic or hypoxic (1%O2) conditions, the cells were incubated with 20Î¼M of DCFDA at 37{degree sign}C for 30min. The culture medium was then removed, and the cells were washed twice with Hank's buffered salt solution. The fluorescence intensity of the cells in each well was determined using a Spectromax plate reader with excitation at 495nm and emission at 529nm. Thereafter cell viability was determined by AlamarBlue assay and DCF fluorescence was normalized to the viability. Results are expressed as a percentage of fluorescence intensity with respect to the cells under normoxic conditions. Error bars indicate SEM from three independent experiments. *P<0.01 (t test).
Supplementary methods from A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
Authors: Gullà Annamaria , Di Martino Maria Teresa , Gallo Cantafio Maria Eugenia , Morelli Eugenio , Amodio Nicola , Botta Cirino , Pitari Maria Rita , Lio Santo Giovanni , Britti Domenico , Stamato Maria Angelica , Hideshima Teru , Munshi Nikhil C. , Anderson Kenneth C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

Supplementary methods for pubblication only
Supplementary Tables S1-2 from Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
Authors: Kluger Harriet M. , Zito Christopher R. , Barr Meaghan L. , Baine Marina K. , Chiang Veronica L.S. , Sznol Mario , Rimm David L. , Chen Lieping , Jilaveanu Lucia B.
Published: April 2023

Supplementary Tables S1-2. Table S1 Multivariable Cox proportional hazards analysis of CD3TIls and other variables Table S2 Multivariable Cox proportional hazards analysis of CD8TIls and other variables
Supplementary Figure S5 from Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2
Authors: Terashima Masato , Togashi Yosuke , Sato Katsuaki , Mizuuchi Hiroshi , Sakai Kazuko , Suda Kenichi , Nakamura Yu , Banno Eri , Hayashi Hidetoshi , De Velasco Marco A. , Fujita Yoshihiko , Tomida Shuta , Mitsudomi Tetsuya , Nishio Kazuto
Published: April 2023

Influence of a proteasome inhibitor on cellular growth in transfectant HEK293 cell lines. Cellular growth was examined using an MTT assay with or without stimulation with collagen I or MG132 (a proteasome inhibitor). Without collagen I, no significant difference in proliferation was observed among the transfectant cell lines even with MG132. With collagen I alone, the cellular growth of the HEK293-DDR2 WT cell line was significantly reduced, compared with that of the HEK293-EGFP or HEK293-DDR2 E655K cell line. When the cells were stimulated with MG132, a significant growth inhibitory effect of collagen I in the HEK293-DDR2 E655K cell line was observed, similar to that in the HEK293-DDR2 WT cell line, compared with that in the HEK293-EGFP cell line. Columns, mean of independent triplicate experiments; Bars, SD; *, P < 0.05; n.s., not significant.
Supplementary information from PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation
Authors: Wu De-Wei , Wu Tzu-Chin , Chen Chih-Yi , Lee Huei
Published: April 2023

Supplementary Fig. 1. PAK1 confers erlotinib resistance in lung adenocarcinoma cells regardless of EGFR mutation Supplementary Fig. 2. The optimal concentration of gefitinib was obtained from the dose-dependent experiments Supplementary Fig. 3. PAK1 transcription is regulated by the PI3K/AKT/C/EBP-β /miR-145 cascades and PAK1 targeted by miR-145 may confer PAK1-mediated TKI resistance in EGFR-wild-type cells Supplementary Fig. 4. PAK1 modulates Mcl-1 protein stability via phosphorylation of Mcl-1 at Ser-159. Supplementary Fig. 5. The association of PAK1 and E-cadherin mRNA expression with overall survival (OS) and relapse free survival (RFS) in lung adenocarcinoma patients. Supplementary Table 1. Relationships of PAK1 and E-cadherin mRNA levels with clinico-pathological parameters, and the association between PAK1 and E-caherin mRNA levels in lung adenocarcinoma patients. Supplementary Table 2. The association of PAK1 and E-cadherin mRNA level with the response to TKI therapy in lung adenocarcinoma patients. Supplementary Table 3. Cox regression analysis for the prognostic value of PAK1 and E-cadherin mRNA levels on OS and RFS in lung adenocarcinoma patients.
Table S4 from Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Authors: Capelletti Marzia , Dodge Michael E. , Ercan Dalia , Hammerman Peter S. , Park Seung-Il , Kim Jhingook , Sasaki Hidefumi , Jablons David M. , Lipson Doron , Young Lauren , Stephens Phil J. , Miller Vincent A. , Lindeman Neal I. , Munir Kiara J. , Richards William G. , Jänne Pasi A.
Published: April 2023

Table S4. Characteristics of identified genomic rearrangements. The KIF5B-RET and the CD74-NTRK1 cases have been previously published (8, 15).
Table S2 from Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Authors: Capelletti Marzia , Dodge Michael E. , Ercan Dalia , Hammerman Peter S. , Park Seung-Il , Kim Jhingook , Sasaki Hidefumi , Jablons David M. , Lipson Doron , Young Lauren , Stephens Phil J. , Miller Vincent A. , Lindeman Neal I. , Munir Kiara J. , Richards William G. , Jänne Pasi A.
Published: April 2023

Table S2. Genomic alterations across 576 lung adenocarcinomas grouped by ethnicity with description of the EGFR mutations. . "*" The "Unknown" population is the same of the pan-WT reported in the text.
Supplementary Table 1, Figures 1-5 from Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy
Authors: Chen Hui-Ming , Ma Ge , Gildener-Leapman Neil , Eisenstein Samuel , Coakley Brian A. , Ozao Junko , Mandeli John , Divino Celia , Schwartz Myron , Sung Max , Ferris Robert , Kao Johnny , Wang Lu-Hai , Pan Ping-Ying , Ko Eric C. , Chen Shu-Hsia
Published: April 2023

Supplementary Table 1. Characteristics of the enrolled patients. Supplementary Figure 1. PBMCs were obtained from patients enrolled in the clinical trials at time points A (pre-sunitinib treatment), B (7 days post-sunitinib treatment), and C (6-30 days post-SBRT). Supplementary Figure 2. The number of pSTAT1+ in CD33+CD14+CD16+ (upper panels) and CD33+CD14+CD16- (lower panels) cells in PBMC from all patients and sunitinib-responders and non-responders based on Tbet+ CD4 T cell-criteria, was determined at the indicated time points. (*p < 0.05; ***p < 0.001) Supplementary Figure 3. The percentage and cell numbers of CD33+CD11b+ Supplementary Figure 4. The percentage of Tbet-expressing CD4 and CD8 T cells in PBMC from all patients, and patients who were separated into sunitinib-responders and non-responders was determined at the indicated time points based on the myeloid cell-based classification Supplementary Figure 5.(A) Mouse monocytic MDSC were left untreated (red) or treated with sunitinib (250 nM, blue) for 48 hrs. The apoptotic cells (Annexin V+) and phosphorylated STAT3 were assessed by flow cytometry. (B) Flow cytometric histogram of CD206+ in CD33+CD14+CD16- (blue) and CD33+CD14+CD16+ (red) populations (left panel). Mean fluorescent intensity of CD206+ was shown on the right panel. (C) Human CD33+CD14+CD16- and CD33+CD14+CD16+ populations were sorted from total PBMC. The mRNA expression of iNOS, MRC1, ARG1 and ARG2 were standardized as the fold changes using CD33+CD14+CD16- population as the base line. (C) The suppressive activity of sorted human CD33+CD14+CD16+ cells against the proliferation of autologous CD4+ T cells in the presence or absence of arginase inhibitor (Nor-NOHA, 100microM) was presented. (*p < 0.05; ***p < 0.001)
Supplementary Figure Legend from Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy
Authors: Chen Hui-Ming , Ma Ge , Gildener-Leapman Neil , Eisenstein Samuel , Coakley Brian A. , Ozao Junko , Mandeli John , Divino Celia , Schwartz Myron , Sung Max , Ferris Robert , Kao Johnny , Wang Lu-Hai , Pan Ping-Ying , Ko Eric C. , Chen Shu-Hsia
Published: April 2023

supplemental figure legend
Supplementary Appendix List and Supplemental Methods from Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
Authors: Toledo Rodrigo A. , Qin Yuejuan , Cheng Zi-Ming , Gao Qing , Iwata Shintaro , Silva Gustavo M. , Prasad Manju L. , Ocal I. Tolgay , Rao Sarika , Aronin Neil , Barontini Marta , Bruder Jan , Reddick Robert L. , Chen Yidong , Aguiar Ricardo C.T. , Dahia Patricia L.M.
Published: April 2023

Supplementary Appendix: List of all supplementary data files; Supplemental Methods: Additional clinical details of Samples, and details of whole exome sequencing, targeted sequencing and in silico structure modeling not included in main article
Table S1 from Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
Authors: Janakiram Murali , Chinai Jordan M. , Fineberg Susan , Fiser Andras , Montagna Cristina , Medavarapu Ramadevi , Castano Ekaterina , Jeon Hyungjun , Ohaegbulam Kim C. , Zhao Ruihua , Zhao Aimin , Almo Steven C. , Sparano Joseph A. , Zang Xingxing
Published: April 2023

Table S1. Expression of cell surface HHLA2 protein in various human cells lines determined by flow cytometry.
Supplementary Figure 2 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Authors: Tramm Trine , Mohammed Hayat , Myhre Simen , Kyndi Marianne , Alsner Jan , Børresen-Dale Anne-Lise , Sørlie Therese , Frigessi Arnoldo , Overgaard Jens
Published: April 2023

Flowchart of patients included in the validation set.
Supplementary table 2 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Authors: Moreno García Victor , Olmos David , Gomez-Roca Carlos , Cassier Philippe A. , Morales-Barrera Rafael , Del Conte Gianluca , Gallerani Elisa , Brunetto Andre T. , Schöffski Patrick , Marsoni Silvia , Schellens Jan H.M. , Penel Nicolas , Voest Emile , Evans Jeffrey , Plummer Ruth , Wilson Richard H. , Soria Jean Charles , Tabernero Josep , Verweij Jaap , Kaye Stan B.
Published: April 2023

Supplementary table 2. Multivariate model for overall survival (Molecularly Targeted Agents).
supplemental legend from DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers
Authors: de Cubas Aguirre A. , Korpershoek Esther , Inglada-Pérez Lucia , Letouzé Eric , Currás-Freixes Maria , Fernández Agustin F. , Comino-Méndez Iñaki , Schiavi Francesca , Mancikova Veronika , Eisenhofer Graeme , Mannelli Massimo , Opocher Guiseppe , Timmers Henri , Beuschlein Felix , de Krijger Ronald , Cascon Alberto , Rodríguez-Antona Cristina , Fraga Mario F. , Favier Judith , Gimenez-Roqueplo Anne-Paule , Robledo Mercedes
Published: April 2023

supplemental legend
Supplementary Figure 1 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Authors: Moreno García Victor , Olmos David , Gomez-Roca Carlos , Cassier Philippe A. , Morales-Barrera Rafael , Del Conte Gianluca , Gallerani Elisa , Brunetto Andre T. , Schöffski Patrick , Marsoni Silvia , Schellens Jan H.M. , Penel Nicolas , Voest Emile , Evans Jeffrey , Plummer Ruth , Wilson Richard H. , Soria Jean Charles , Tabernero Josep , Verweij Jaap , Kaye Stan B.
Published: April 2023

Supplementary Figure 1. Study flowchart
Supplemental Table 1 from DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers
Authors: de Cubas Aguirre A. , Korpershoek Esther , Inglada-Pérez Lucia , Letouzé Eric , Currás-Freixes Maria , Fernández Agustin F. , Comino-Méndez Iñaki , Schiavi Francesca , Mancikova Veronika , Eisenhofer Graeme , Mannelli Massimo , Opocher Guiseppe , Timmers Henri , Beuschlein Felix , de Krijger Ronald , Cascon Alberto , Rodríguez-Antona Cristina , Fraga Mario F. , Favier Judith , Gimenez-Roqueplo Anne-Paule , Robledo Mercedes
Published: April 2023

Supplemental Table 1. Detailed clinical data for PPGL samples.
Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Authors: Jethava Yogesh S. , Mitchell Alan , Epstein Joshua , Zangari Maurizio , Yaccoby Shmuel , Tian Erming , Waheed Sarah , Khan Rashid , Papanikolaou Xenofon , Grazziutti Monica , Cottler-Fox Michele , Petty Nathan , Steward Douglas , Panozzo Susan , Bailey Clyde , Hoering Antje , Crowley John , Sawyer Jeffrey , Morgan Gareth , Barlogie Bart , van Rhee Frits
Published: April 2023

Supplementary Figure 1: Consort flow diagram of patient flow through TT4 arms Supplementary Figure 2: Cumulative Incidence of Death and Post-Relapse Survival (P-values for S-TT4 vs L-TT4; TRM, p = 0.61; MRM, p = 0.70; OIM, p = 0.25). Supplementary Figure 3: Clinical outcomes according to the presence of PETidentified focal lesions (FL; =<3 v >3) by TT4 arm Supplementary Figure 4: Ingenuity pathways identified a network of 8 interrelated genes.
Supplemental Table 1 from Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell–Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
Authors: Wennerberg Erik , Pfefferle Aline , Ekblad Lars , Yoshimoto Yuya , Kremer Veronika , Kaminskyy Vitaliy O , Juhlin C Christofer , Höög Anders , Bodin Inger , Svjatoha Vitalijs , Larsson Catharina , Zedenius Jan , Wennerberg Johan , Lundqvist Andreas
Published: April 2023

Supplemental Table 1. NK cell specific lysis of human cell lines. Effector-to-target ratio = 3:1. Co-culture = 18h. ATC = anaplastic thyroid carcinoma, PTC = papillary thyroid carcinoma, CML = Chronic myelogenous leukemia: SD = standard deviation.
Supplemental Video M3 from A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment
Authors: Witney Timothy H. , Hoehne Aileen , Reeves Robert E. , Ilovich Ohad , Namavari Mohammad , Shen Bin , Chin Frederick T. , Rao Jianghong , Gambhir Sanjiv S.
Published: April 2023

Supplemental Video M3. 18FML-10 uptake in naive tumors
Supplemental Video M2 from A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment
Authors: Witney Timothy H. , Hoehne Aileen , Reeves Robert E. , Ilovich Ohad , Namavari Mohammad , Shen Bin , Chin Frederick T. , Rao Jianghong , Gambhir Sanjiv S.
Published: April 2023

Supplemental Video M2. 18FFDG uptake in drug-treated tumors
Supplementary Figure 1 from The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Authors: Niederst Matthew J. , Hu Haichuan , Mulvey Hillary E. , Lockerman Elizabeth L. , Garcia Angel R. , Piotrowska Zofia , Sequist Lecia V. , Engelman Jeffrey A.
Published: April 2023

Supplementary Figure 1. EGFR amplification status and variant allele frequencies of T790M and C797S mutations for MGH121 parental and MGH121 resistant #1 cells.
Supplementary Materials from Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays
Authors: Srivastava Apurva K. , Hollingshead Melinda G. , Weiner Jennifer , Navas Tony , Evrard Yvonne A. , Khin Sonny A. , Ji Jiuping Jay , Zhang Yiping , Borgel Suzanne , Pfister Thomas D. , Kinders Robert J. , Bottaro Donald P. , Linehan W. Marston , Tomaszewski Joseph E. , Doroshow James H. , Parchment Ralph E.
Published: April 2023

Table S1: Summary of analytical characteristics of full-length MET and pMET assays; data collected from assays run with A549, U87, SNU5 and GTL-16 xenograft tumor extracts. Table S2: Measurement of MET and pMET levels in core needle specimens (#1-5) of a resected human HPRC tumor harboring a germ line mutation in MET (H1112R) Table S3: Measurement of mouse MET and pMET species by the MET immunoassays Figure legends
Supplementary Figure 1 from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Authors: Vallera Daniel A. , Felices Martin , McElmurry Ron , McCullar Valarie , Zhou Xianzheng , Schmohl Joerg Uwe , Zhang Bin , Lenvik Alexander J. , Panoskaltsis-Mortari Angela , Verneris Michael R. , Tolar Jakub , Cooley Sarah , Weisdorf Daniel J. , Blazar Bruce R. , Miller Jeffrey S.
Published: April 2023

Supplementary Figure 1. To address the input of the IL-15 moiety on NK cell cytotoxicity, we compared the 161533 TriKE to equivalent molar concentrations of IL-15 or IL-15 plus 1633 BiKE. Activation markers were studied.
Supplemental Table 1 from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Authors: Vallera Daniel A. , Felices Martin , McElmurry Ron , McCullar Valarie , Zhou Xianzheng , Schmohl Joerg Uwe , Zhang Bin , Lenvik Alexander J. , Panoskaltsis-Mortari Angela , Verneris Michael R. , Tolar Jakub , Cooley Sarah , Weisdorf Daniel J. , Blazar Bruce R. , Miller Jeffrey S.
Published: April 2023

BiKE and TriKE selectively bind antigen expressing targets
Supplementary Figures S1-6 from TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients
Authors: Hossain Dewan M. S. , Pal Sumanta K. , Moreira Dayson , Duttagupta Priyanka , Zhang Qifang , Won Haejung , Jones Jeremy , D'Apuzzo Massimo , Forman Stephen , Kortylewski Marcin
Published: April 2023

Supplementary Figures S1-6. Supplementary Figure S1. The effect of the freezing/thawing procedure on CD15 and CD33 marker staining on human PBMCs. Supplementary Figure S2. Time- and plasma concentration-dependent restoration of STAT3 activity in previously frozen G-MDSCs. Supplementary Figure S3. Immune cell populations accumulating in peripheral blood of mCRPC patients. Supplementary Figure S4. Effect of docetaxel treatment on granulocytic MDSCs in mCRPC patients. Supplementary Figure S5. CD15HI granulocytic myeloid cells isolated from prostate cancer patients inhibit proliferation of allogeneic T cells. Supplementary Figure S6. Direct cytotoxic effect of CpG-STAT3 siRNA on patient derived granulocytic MDSCs.